Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial

oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]

AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.